The first day of the 5th annual CAR- T cell meeting in Rotterdam turned out to be rather interesting indeed with a number of key presentations highlighting novel developments across a range of hematologic malignancies.

If we want to see some progress then we need to start developing new constructs with other targets beyond CD19 and CD20, which are applicable to B cell malignancies, CD123 and CD33 in AML, and BCMA in multiple myeloma.

By the way, sometimes gene edited allogeneic products might make sound scientific sense in the context of the disease being studied, but getting these through the various regulatory hoops and hurdles isn’t as easy as some might think.

Necessity is often the mother of invention requiring alternative strategies to creatively address the underlying challenges.

Here we highlight some of these developments and put them in a broader context of the evolving CAR-T cell therapy field…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by